Journal of Clinical Oncology, Vol 13, 2166-2173, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer

TJ Smith, BE Hillner, DM Neighbors, PA McSorley and T Le Chevalier
Department of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond 23298-0037, USA.

PURPOSE: To estimate the comparative cost-effectiveness of three regimens for metastatic non-small-cell lung cancer (NSCLC). METHODS: Results from a randomized clinical trial of 612 European patients with NSCLC, and cost data from an academic cancer center, the Medical College of Virginia, were analyzed. In this post-hoc economic analysis, we compared vinorelbine alone, vinorelbine plus cisplatin, and a common regimen of vindesine plus cisplatin. RESULTS: Vinorelbine plus cisplatin resulted in the longest mean survival time of the three regimens, 49.6 weeks, followed by vindesine plus cisplatin, 44.3 weeks, and vinorelbine, 41.6 weeks. Compared with vinorelbine alone, vinorelbine plus cisplatin added 56 days at a cost of $2,700, resulting in a cost-effectiveness ratio of $17,700 per year of life gained. Similarly, vindesine plus cisplatin added 19 days at a cost of $1,150, or $22,100 per year of life gained. Compared with vindesine plus cisplatin, vinorelbine plus cisplatin added 37 days at a cost of $1,570, or $15,500 per year of life gained. CONCLUSION: The most effective regimen of vinorelbine plus cisplatin added substantial benefit compared with vinorelbine alone or another common treatment, vindesine plus cisplatin, at a cost-effectiveness within accepted limits for medical interventions. Vindesine plus cisplatin also added benefit at an acceptable cost per year of life gained. If vinorelbine is preferred because of its toxicity profile, the additional effectiveness of cisplatin added substantial benefit at an acceptable cost. Compared with other common medical interventions, chemotherapy for NSCLC has acceptable efficacy and cost-effectiveness and should not be arbitrarily denied based on clinical or economic grounds.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. C. Earle Outcomes Research in Lung Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77. [Abstract] [Full Text] [PDF]

				S. Verma and A. L. Ilersich Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer Oncologist, June 1, 2003; 8(3): 232 - 240. [Abstract] [Full Text] [PDF]

				M. K. Gould, G. D. Sanders, P. G. Barnett, C. E. Rydzak, C. C. Maclean, M. B. McClellan, and D. K. Owens Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules Ann Intern Med, May 6, 2003; 138(9): 724 - 735. [Abstract] [Full Text] [PDF]

				N. B. Leighl, F. A. Shepherd, R. Kwong, R. L. Burkes, R. Feld, and P. J. Goodwin Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1344 - 1352. [Abstract] [Full Text] [PDF]

				S. D. Ramsey, C. M. Moinpour, L. C. Lovato, J. J. Crowley, P. Grevstad, C. A. Presant, S. E. Rivkin, K. Kelly, and D. R. Gandara Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, February 20, 2002; 94(4): 291 - 297. [Abstract] [Full Text] [PDF]

				A Clegg, D A Scott, P Hewitson, M Sidhu, and N Waugh Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review Thorax, January 1, 2002; 57(1): 20 - 28. [Abstract] [Full Text] [PDF]

				B. E. Hillner, S. Agarwala, and M. R. Middleton Post Hoc Economic Analysis of Temozolomide Versus Dacarbazine in the Treatment of Advanced Metastatic Melanoma J. Clin. Oncol., April 7, 2000; 18(7): 1474 - 1480. [Abstract] [Full Text] [PDF]

				E. M. Remer, N. Obuchowski, J. D. Ellis, T. W. Rice, D. J. Adelstein, and M. E. Baker Adrenal Mass Evaluation in Patients with Lung Carcinoma: A Cost-Effectiveness Analysis Am. J. Roentgenol., April 1, 2000; 174(4): 1033 - 1039. [Abstract] [Full Text] [PDF]

				R. J. Gralla Silk Purse in Atlanta: A Commentary on SWOG 9509, An Advanced Non-Small Cell Lung Cancer Trial Oncologist, June 1, 1999; 4(3): 188 - 190. [Full Text]

				S. C. Malfair Taylor "C" is for costs, and cancer, and conference: Highlights of the First European Conference on the Economics of Cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 125 - 128. [Abstract] [PDF]